Research Perspectives:

This article has been corrected. Correction in: Oncotarget. 2018; 9:32400.

Will PI3K pathway inhibitors be effective as single agents in patients with cancer?

Joan T. Garrett, Anindita Chakrabarty and Carlos L. Arteaga _

PDF  |  HTML  |  How to cite

Oncotarget. 2011; 2:1314-1321. https://doi.org/10.18632/oncotarget.409

Metrics: PDF 3300 views  |   HTML 3148 views  |   ?  


Joan T. Garrett1, Anindita Chakrabarty1 and Carlos L. Arteaga1,2,3

1 Department of Medicine, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

2 Department of Cancer Biology, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

3 Breast Cancer Research Program, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN, USA

Received: November 23, 2011; Accepted: November 30, 2011; Published: December 31, 2011;

Keywords: cancer, combination therapy, mTOR, PI3K, receptor tyrosine kinases, oncotarget


Carlos L. Arteaga, email:


The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) axis regulates essential cellular functions including cell survival, proliferation, metabolism, migration, and angiogenesis. The PI3K pathway is activated in human cancers by mutation, amplification, and deletion of genes encoding components of this pathway. The critical role of PI3K in cancer has led to the development of drugs targeting the effector mechanisms of this signaling network. Recent studies have shown that inhibition at multiple levels of the PI3K pathway results in FOXO-dependent feedback reactivation of several receptor tyrosine kinases (RTKs) which, in turn, limit the sustained inhibition of this pathway and attenuates the action of therapeutic antagonists. This suggests that if used as single agents, PI3K pathway inhibitors may have limited clinical activity. We propose herein that to successfully target the output of the PI3K pathway in cancer cells, combination therapies that hinder these compensatory mechanisms should be used. Thus, combination therapies that target RTKs, PI3K, and mTOR activities may be required to maximize the clinical benefit derived from treatment with these inhibitors.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 409